Larta Institute's Life Science Practice
Larta
Institute’s ongoing and extensive connection within the early-stage life
science community is rooted in programs & services that address the
needs of key stakeholders (our customers) across the entire continuum of
discovery, nurture, and development of new products, technologies, and
services that address unmet human health challenges worldwide.
| Life Science Program Success |
Innovators
The National Institutes of Health Commercialization Assistance Program (http://www.larta.org/nihcap.asp) is a nationwide ten-month program funded by NIH and managed and executed by Larta Institute. The program is designed to assist a select group of the most promising life science companies bring their technologies to market. The program comprises of training workshops, individual mentoring and consulting sessions, and public events in which companies present their technologies to the investment community, potential strategic partners and licensees.
Other commercialization programs clients include the National Institute of Standards and Technology (http://www.larta.org/atp), the Defense Advanced Research Projects Agency (http://www.larta.org/darpa) and the Department of Agriculture (http://www.larta.org/usda), which fund cutting-edge innovation in the life science and related sectors. In addition, Larta Institute also manages Network T2 (www.larta.org/networkt2.asp), a consortium of university technology transfer executives focused on facilitating licensing and partnership alliances with industry.
Industry & Investment Partners
Larta Institute enjoys deep relationships with high level licensing, business development, and scientific executives within the life science community, who look to Larta to source, access, and meaningfully engage with companies at the cusp of cutting edge innovation. Our partners include Genentech, Genzyme, Johnson & Johnson, GlaxoSmithKline, Novartis, Pfizer, Medtronic, Amgen, Merck, Biogen Idec, Procter & Gamble, Baxter, Allergan, Boston Scientific, Invitrogen, BD Biosciences. Larta also maintains relationships with life science-focused capital providers across the U.S. to identify early-stage opportunities on a year-round basis.
Global Life Science Innovation
Larta Institute’s Global Bridge™ Programs (www.larta.org/globalbridge.asp) assist research institutes and technology centers around the world in accelerating the commercial potential of their most promising life science spinouts. Larta Institute’s transactional relationships with clients provide access and insight into global life science efforts and opportunities where innovation is applied to commercial market opportunities. Global Bridge partnerships: Korea (Korea Research Institute of Bioscience and Biotechnology), New Zealand (Foundation for Research Science and Technology), Taiwan (Institute for Information Industry), Israel (U.S.-Israel Science & Technology Foundation), Canada (Western Diversification, Canada), and others.
Showcasing Emerging Innovations
Now 14 years strong, The Venture Forum is the largest - and longest running - showcase of early stage innovation and entrepreneurship. It is the must-attend event for those seeking access to untapped quality deal flow from around the world. Venture Forum presenting companies are drawn from Larta's robust pipeline, and prepared by world-class mentors to deliver presentations focused on a solid business proposition, excellent science, and strong growth potential for an audience of investors, partners and customers. Larta Institute's commercialization practice advises hundreds of innovative companies with breakthrough technologies funded by or spinning out of U.S. Federal Agencies, universities and research institutes, and innovative regions from across the globe. The 2007 Forum attracted 850 attendees and featured over 120 presenting companies.
For more information visit www.larta.org
